-
Kicking Drug Resistance to the Curb in RET-positive Lung Cancer
Read time: 4 minutes
Lung cancers that test positive for the RET biomarker are often treated with targeted therapy. While this type of treatment has improved the duration and quality of life for many...
IN THE SPOTLIGHT
-
Leveraging Basic Science to Stop Drug Resistance in RET+ Lung Cancer
Advances in targeted therapies have allowed us to treat some types of lung cancer with mutations in specific genes (for example, EGFR, KRAS, and RET). This has given some patients... -
Highlights of AACR 2024: Where the Laboratory Meets the Patient
Read time: 7 minutes It’s spring! The daffodils bloom, the days become longer, and I attend the annual meeting of the American Association for Cancer Research (AACR). For those of... -
Chemo Shortage Didn’t Materialize ‘The Way We Initially Feared’
This March, LUNGevity Foundation partnered with CURE for their “Speaking Out” video series, inviting Amy Moore, PhD, vice president of global engagement and patient partnerships at... -
FDA Grants Accelerated Approval for HER2+ Cancer Treatment
On April 5, 2024, the US Food and Drug Administration (FDA) announced the accelerated approval of fam-trastuzumab deruxtecan-nxki (Enhertu®) to treat patients with unresectable or... -
Caregivers: Planning the Self-Care Journey
This webinar explains the phases of the caregiving cycle and offers tips and strategies for meeting the challenges of each phase. The discussion features Michelle Bolden, founder... -
Cancer Grand Challenges Summit 2024: No Time to Waste in Addressing Some of Toughest Challenges in Cancer
Read time: 4 minutes I just returned from the Cancer Grand Challenges Summit, held March 5–8, 2024 in London, England. Cancer Grand Challenges was launched in 2020 as a... -
Leveraging Genetics to Understand Why Younger Adults Are Developing Lung Cancer
Read Time: 5 minutes It’s a mystery that has been baffling researchers: Why do some people develop lung cancer in their 20s or 30s? While we used to think lung cancer was only... -
Lung Cancer Masterclass: Get Smart About Lung Cancer
In the past five years, the lung cancer community has seen an astonishing number of new treatments. As our understanding of lung cancer has deepened, the older treatment approaches... -
Rare Mutations (RET, ROS1, MET, BRAF) Virtual Meetup
Rare Mutation (RET, ROS1, MET, BRAF) patients/survivors - Join us the 1st Wednesday of every month to c onnect with others who share common experiences and build your community...
Let Your Voice Be Heard!
Let Your Voice Be Heard!
We are collecting stories from patients, caregivers, friends, and family members! Tell us how lung cancer has affected your life. Email your story to us at support@lungevity.org. Thanks!
RET, MET, and EGFR: An unusual tale of three oncogenes in lung cancer
RET, MET, and EGFR: An unusual tale of three oncogenes in lung cancer
LUNGevity's Upal Basu Roy, PhD, MPH, Executive Director, Research, discusses innovative research into RET+ NSCLC with patient advocates and the scientist conducting the studies. Panelists include Omaima Salous (diagnosed with RET+ NSCLC and co-founder of The Hamoui Foundation), Dr. Hilary Hammell (diagnosed with RET+ NSCLC and co-chair of RETpositive), and Dr. Tejas Patil (Assistant Professor, University of Colorado). The discussion focuses on Dr. Patil’s RET+ NSCLC research project…